{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:45:34Z","timestamp":1791981934158,"version":"4.4.0"},"reference-count":61,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>Hematologic toxicities are common during breast cancer chemotherapy, but data from Ethiopia are limited. This study assessed hematologic toxicities and associated factors among patients treated with doxorubicin\u2010cyclophosphamide followed by paclitaxel (ACT) regimen in Northwest Ethiopia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted among 422 patients with breast cancer treated with the AC\u2010T regimen from January 2019 to August 2023 in Northwest Ethiopia. Data were collected from July to August 2023. Factors associated with hematologic toxicities were identified using binary logistic regression, with adjusted odds ratio (AOR), 95% confidence interval (CI), and a two\u2010sided\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 indicating statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 422 patients, the prevalence of chemotherapy\u2010induced neutropenia (CIN), chemotherapy\u2010induced anemia (CIA), chemotherapy\u2010induced thrombocytopenia (CIT), and neutropenic fever (NF)\u00a0was 61.8%, 44.1%, 16.4%, and 10.0%, respectively. Older age (\u2265\u200943 years) (AOR\u2009=\u20093.5, 95% CI: 2.2\u20135.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) and rural residence (AOR\u2009=\u20093.4, 95% CI: 2.9\u20138.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032) were independently associated with CIN. Advanced cancer stage was associated with FN, with higher odds among patients with stage IV (AOR\u2009=\u20094.4, 95% CI: 1.9\u20139.6,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and stage III disease (AOR\u2009=\u20092.8, 95% CI: 1.6\u20138.2,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016). CIA was significantly associated with mixed histology (AOR\u2009=\u20093.3, 95% CI: 1.3\u20138.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015), lobular histology (AOR\u2009=\u20091.7, 95% CI: 1.1\u20132.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033), stage III cancer (AOR\u2009=\u20092.5, 95% CI: 1.2\u20135.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017) and stage IV cancer (AOR\u2009=\u20093.4, 95% CI: 1.1\u201310.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028), and comorbidities (AOR\u2009=\u20091.8, 95% CI: 1.1\u20133.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040). CIT was associated with older age (\u2265\u200943 years) (AOR\u2009=\u20092.8, 95% CI: 1.4\u20135.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), rural residence (AOR\u2009=\u20094.8, 95% CI: 1.6\u201314.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), stage III (AOR\u2009=\u20092.8, 95% CI: 1.1\u20137.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028), and stage IV disease (AOR\u2009=\u20094.5, 95% CI: 1.4\u201310.1,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hematologic toxicities were common with the ACT regimen and associated with older age, rural residence, advanced stage, comorbidities, and lobular\/mixed histology, warranting close monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.73264","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:49:17Z","timestamp":1790830157000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic Toxicities and Determinants Among Patients With Breast Cancer Treated With Doxorubicin\u2013Cyclophosphamide Followed by Paclitaxel in Northwest Ethiopia: A Retrospective Cohort Study"],"prefix":"10.1002","volume":"9","author":[{"given":"Tegenu Chanie","family":"Tesfaye","sequence":"first","affiliation":[{"name":"Department of Pharmacy College of Health Sciences, Debre Markos University Debre Markos Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-2951","authenticated-orcid":false,"given":"Rahel Belete","family":"Abebe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, College of Medicine and Health Sciences, University of Gondar Gondar Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gashaw Binega","family":"Mekonnen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, College of Medicine and Health Sciences, University of Gondar Gondar Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrem Tafesse","family":"Teferi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine School of Medicine, College of Medicine and Health Sciences, University of Gondar Gondar Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-1771","authenticated-orcid":false,"given":"Mekonnen Melkie","family":"Bizuneh","sequence":"additional","affiliation":[{"name":"Department of Reproductive Health School of Public Health, College of Medicine and Health Sciences, Bahir Dar University Bahir Dar Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5982-853X","authenticated-orcid":false,"given":"Ashenafi Kibret","family":"Sendekie","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy School of Pharmacy, College of Medicine and Health Sciences, University of Gondar Gondar Ethiopia"},{"name":"Curtin Medical School, Faculty of Health Sciences, Curtin University Bentley Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2616-397X","authenticated-orcid":false,"given":"Tigabu Eskeziya","family":"Zerihun","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Unit Pharmacy Education and Clinical Services Directorate, Debre Tabor University Debre Tabor Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9361-1033","authenticated-orcid":false,"given":"Desalegn Addis","family":"Mussie","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Unit Pharmacy Education and Clinical Services Directorate, Debre Tabor University Debre Tabor Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3431-8187","authenticated-orcid":false,"given":"Abel Temeche","family":"Kassaw","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Unit Pharmacy Education and Clinical Services Directorate, Debre Tabor University Debre Tabor Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-6804","authenticated-orcid":false,"given":"Samuel Agegnew","family":"Wondm","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Unit Pharmacy Education and Clinical Services Directorate, Debre Tabor University Debre Tabor Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"e_1_2_15_2_1","volume-title":"Pharmacotherapy: A Pathophysiologic Approach","author":"Trujillo J.","year":"2020"},{"key":"e_1_2_15_3_1","unstructured":"World Health Organization WHO Report on Cancer: Setting Priorities Investing Wisely and Providing Care for All(WHO 2020)."},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30421"},{"issue":"5","key":"e_1_2_15_5_1","first-page":"1073","article-title":"Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients With Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial","volume":"8","author":"Buzdar A. U.","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.47895\/amp.v49i2.967"},{"key":"e_1_2_15_7_1","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group \u201cComparisons Between Different Polychemotherapy Regimens for Early Breast Cancer: Meta\u2010Analyses of Long\u2010Term Outcome Among 100 000 Women in 123 Randomised Trials \u201dLancet379 no. 9814 (2012): 432\u2013444.","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.92004"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01419-6"},{"key":"e_1_2_15_10_1","unstructured":"P. N. M.Mwangi Incidence Risk Factors and Management of Neutropenia Among Cancer Patients With Solid Tumors Receiving Chemotherapy at Kenyatta National Hospital Cancer Treatment Centre(University of Nairobi 2019)."},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021.1188"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0821-1"},{"issue":"11","key":"e_1_2_15_13_1","first-page":"2210","article-title":"First Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results From a Prospective Nationwide Study","volume":"104","author":"Crawford J.","year":"2004","journal-title":"American Society of Hematology"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2016.19.1.76"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.020"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S89480"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024016508925"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-9-743"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06784.x"},{"issue":"1","key":"e_1_2_15_20_1","article-title":"Frequency of Chemotherapy Induced Anemia in Breast Cancer Patients","volume":"10","author":"Pourali L.","year":"2017","journal-title":"Iranian Journal of Cancer Prevention"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220914710"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13595"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0913-y"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/2636514"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13822"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1165-6"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.200"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449226"},{"key":"e_1_2_15_29_1","unstructured":"S. K.LwangaandS.Lemeshow Sample Size Determination in Health Studies(WHO 1991)."},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.3038"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220907658"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.1734"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_15_35_1","unstructured":"MOH Standard Treatment Guideline for General Hospitals(MOH 2021)."},{"key":"e_1_2_15_36_1","unstructured":"NCCN Cancer and Chemotherapy Induced Anemia(NCCN 2018)."},{"key":"e_1_2_15_37_1","doi-asserted-by":"crossref","unstructured":"C. E.NeunertandN.Cooper \u201cEvidence\u2010Based Management of Immune Thrombocytopenia: ASH Guideline Update \u201dHematology2018 no. 1 (2018): 568\u2013575.","DOI":"10.1182\/asheducation-2018.1.568"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00481"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/20503121221098236"},{"key":"e_1_2_15_40_1","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events v3. 0.(CTCAE)(NCI 2006)."},{"key":"e_1_2_15_41_1","unstructured":"U.S. Department of Health and Human Services and National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0(U.S. Department of Health and Human Services and National Cancer Institute 2019)."},{"key":"e_1_2_15_42_1","unstructured":"U.S. Department of Health and Human Services Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0(National Institutes of Health National Cancer Institute 2009)."},{"key":"e_1_2_15_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000279"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0026"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_156064"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-7-200704030-00004"},{"key":"e_1_2_15_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02938"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030387"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx758"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279512"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07514.x"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11882"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.19.1616"},{"key":"e_1_2_15_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)35201-8"},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.187338"},{"key":"e_1_2_15_57_1","doi-asserted-by":"publisher","DOI":"10.32598\/ijmtfm.v10i3.32256"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00616-3"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1415877"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2861-z"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac030"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102837"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.73264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.73264","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.73264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:49:31Z","timestamp":1791978571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.73264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/hsr2.73264"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.73264","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"2025-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e73264"}}